As lung cancer patients harbouring EGFR mutations would benefit from EGFR inhibition and the expression of PD-L1 allows for treatment with immune checkpoints blockades such as PD-1/PD-L1 inhibitors. This evidence concerns the gene CD274 and lung carcinoma.